Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

LANSOPRAZOLE & CLARITHROMYCIN & AMOXICILLIN

All products: Limited Use (codes 306, 307)

Other products in the same Health Canada class (A02B) — coverage varies; not interchangeable

  • Cimetidine (Cimetidine): general benefit, Not a benefit
  • Famotidine (Pepcid): general benefit, Not a benefit
  • Misoprostol (Cytotec): general benefit, Not a benefit
  • Nizatidine (Axid): general benefit
  • Pantoprazole (Tecta): general benefit
  • Rabeprazole (Pariet): general benefit

7 more in the class list below

AA-LansoprazoleAmoxicillinClarithromycin · DIN 02470780 · 30mg & 500mg & 500mg · tablet/capsule Pk

Limited Use — Reason for Use code 306, 307 requiredMarketed · checked 2026-09-19
StatusLimited Use — Reason for Use code 306, 307 required
Write on scriptLU code 306, 307 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 306, 307
Reason for Use code 306 For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, breath test or endoscopy, for a course of up to 14 days. Maximum duration: 14 days. Coverage limit: LU Authorization Period: 1 year Reason for Use code 307 For the retreatment of H. pylori-positive peptic ulcers where H. pylori recurrence or persistence is documented, by breath test or endoscopy, for a course of up to 14 days. Maximum duration: 14 days (after a four-week period has elapsed since the end of the previous treatment) Coverage limit: Retreatment decisions should be based upon positive symptoms and positive endoscopy or positive urea breath test. Retreatment should not be based on a positive serology test, as serology tests may remain positive indefinitely. An alternative antibiotic regimen is recommended when initial therapy fails due to concerns of antimicrobial resistance. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
AA-LansoprazoleAmoxicillinClarithromycin · DIN 02470780 Manufacturer: A A Pharma Inc.; listing date 2018-09-27 Health Canada: Marketed since 2022-10-04 · brand AA-LANSOPRAZOLE-AMOXICILLIN-CLARITHROMYCIN · ATC A02BD07 LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN · form Kit, Capsule (delayed-release), Tablet, Capsule · route Oral · ingredients LANSOPRAZOLE 30 MG/CAP, AMOXICILLIN 500 MG/CAP, CLARITHROMYCIN 500 MG/TAB · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

AA-LansoprazoleAmoxicillinClarithromycin: Formulary list price $67.9100/unit (unit not stated in source; not the patient's cost)

Ministry pays: $67.9100 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95983 · Verify on the e-Formulary ↗ (DIN 02470780)

Source record
DIN 02470780: AA-LansoprazoleAmoxicillinClarithromycin Raw flags: sec12=Y, sec3=Y Item: 564000091; group id 681; item number 1698; lccId 00104; manufacturer id AAP Source form: Tab/Cap Pk; strength: 30mg & 500mg & 500mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $67.9100; ministry $67.9100 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02470780 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95983
Interchangeable products
Hp-PAC · DIN 02238525 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (56:40 Miscellaneous G.I. Drugs) and how they are covered

Matched class: 56:40 Miscellaneous G.I. Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BUDESONIDE, MESALAZINE, NIZATIDINE, OLSALAZINE SODIUM, PANTOPRAZOLE MAGNESIUM, RABEPRAZOLE SODIUM, SUCRALFATE Some products covered without a code (check the product listing): 5-AMINOSALICYLIC ACID, CIMETIDINE, DOMPERIDONE MALEATE, FAMOTIDINE, LACTULOSE, METOCLOPRAMIDE HCL, MISOPROSTOL, RANITIDINE HCL 56:40 Miscellaneous G.I. Drugs

CIMETIDINE

· 10 products · General benefit (5), Listed, not a benefit (5) · strengths: 200mg, 300mg, 400mg, 600mg, 800mg · Tab

FAMOTIDINE

· 16 products · Listed, not a benefit (2), General benefit (14) · strengths: 20mg, 40mg · Tab

MISOPROSTOL

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mcg, 200mcg · Tab

NIZATIDINE

· 2 products · General benefit · strengths: 150mg, 300mg · Cap

PANTOPRAZOLE MAGNESIUM

· 6 products · General benefit · strengths: 40mg · Ent Coated Tab

RABEPRAZOLE SODIUM

· 16 products · General benefit · strengths: 10mg, 20mg · Tab

RANITIDINE HCL

· 23 products · Listed, not a benefit (3), General benefit (20) · strengths: 15mg/mL, 150mg, 300mg · Oral Sol, Tab

SUCRALFATE

· 4 products · General benefit · strengths: 1g/5mL, 1g · Oral Susp, Tab

LANSOPRAZOLE

· 16 products · Limited Use, codes 293, 295, 297, 401, 402 · strengths: 15mg, 30mg · DR Cap

OMEPRAZOLE

· 19 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (2), Limited Use, codes 293, 297, 401, 402 (13) · strengths: 10mg, 20mg · DR Cap

PANTOPRAZOLE SODIUM

· 30 products · Off-Formulary Interchangeable, not an ODB benefit (10), Limited Use, codes 293, 295, 297, 401, 402 (20) · strengths: 20mg, 40mg · Ent Tab

DEXLANSOPRAZOLE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 30mg, 60mg · DR Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:40 and 10 more
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:22 Antiemetics and Antinauseants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS The components of the AA-LANSOPRAZOLE-AMOXICILLIN-CLARITHROMYCIN [lansoprazole delayed-release capsules, in combination with clarithromycin tablets plus amoxicillin capsules as triple therapy], are indicated for: ● the treatment of patients with Helicobacter pylori (H. pylori) infection and active duodenal ulcer disease. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence (see 14.1 Clinical Trials by Indication and 4 DOSAGE AND ADMINISTRATION). In patients with a recent history of duodenal ulcers who are H. pylori positive, eradication therapy may reduce the rate of recurrence of duodenal ulcers. The optimal timing for eradication therapy for such patients remains to be determined. In patients who fail a therapy combination containing clarithromycin, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, an alternative therapy combination is recommended. Resistance to amoxicillin has not been demonstrated in clinical studies with lansoprazole delayed-release capsules and amoxicillin. Table 1 summarizes the eradication rates for th… https://pdf.hres.ca/dpd_pm/00077480.PDF PM date: OCT 18, 2024 Source product: AA-LANSOPRAZOLE-AMOXICILLIN-CLARITHROMYCIN; DIN 02470780; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.